FreshRSS

🔒
❌ Acerca de FreshRSS
Hay nuevos artículos disponibles. Pincha para refrescar la página.
AnteayerTus fuentes RSS

Non-English speakers are not adequately represented in paediatric research

Por: Paquette · E. · Pilarz · M.

Commentary on: Chen A, Demaestri S, Schweiberger K, Sidani J, et al. Inclusion of non-English-speaking participants in pediatric health research: a review. JAMA Pediatr. 2023;177(1):81–88. doi: 10.1001/jamapediatrics.2022.3828.

Implications for practice and research

  • In a review of inclusion of non-English speaking (NES) participants, 9% of research articles included NES participants, which may impact study generalisability.

  • Research teams, research networks/databases, regulatory authorities and journals that disseminate study findings share responsibility for adequate inclusion of NES participants in research.

  • Context

    Non-English speakers (NES) and limited English proficiency (LEP) populations are growing.1 Children from NES/LEP families are vulnerable to health disparities and experience poorer health.2 It is important to provide equitable care to NES/LEP populations. Generating applicable evidence requires inclusion of NES/LEP populations in research. However, inclusion of NES/LEP populations in research is understudied. Additionally, unlike requirements to justify exclusion of other populations, inclusion...

    Evidence for clinician underprescription of and patient non-adherence to guideline-recommended cardiovascular medications among adults with peripheral artery disease: protocol for a systematic review and meta-analysis

    Por: de Launay · D. · Paquet · M. · Kirkham · A. M. · Graham · I. D. · Fergusson · D. A. · Nagpal · S. K. · Shorr · R. · Grimshaw · J. M. · Roberts · D. J.
    Introduction

    International guidelines recommend that adults with peripheral artery disease (PAD) be prescribed antiplatelet, statin and antihypertensive medications. However, it is unclear how often people with PAD are underprescribed these drugs, which characteristics predict clinician underprescription of and patient non-adherence to guideline-recommended cardiovascular medications, and whether underprescription and non-adherence are associated with adverse health and health system outcomes.

    Methods and analysis

    We will search MEDLINE, EMBASE and Evidence-Based Medicine Reviews from 2006 onwards. Two investigators will independently review abstracts and full-text studies. We will include studies that enrolled adults and reported the incidence and/or prevalence of clinician underprescription of or patient non-adherence to guideline-recommended cardiovascular medications among people with PAD; adjusted risk factors for underprescription of/non-adherence to these medications; and adjusted associations between underprescription/non-adherence to these medications and outcomes. Outcomes will include mortality, major adverse cardiac and limb events (including revascularisation procedures and amputations), other reported morbidities, healthcare resource use and costs. Two investigators will independently extract data and evaluate study risk of bias. We will calculate summary estimates of the incidence and prevalence of clinician underprescription/patient non-adherence across studies. We will also conduct subgroup meta-analyses and meta-regression to determine if estimates vary by country, characteristics of the patients and treating clinicians, population-based versus non-population-based design, and study risks of bias. Finally, we will calculate pooled adjusted risk factors for underprescription/non-adherence and adjusted associations between underprescription/non-adherence and outcomes. We will use Grading of Recommendations, Assessment, Development and Evaluation to determine estimate certainty.

    Ethics and dissemination

    Ethics approval is not required as we are studying published data. This systematic review will synthesise existing evidence regarding clinician underprescription of and patient non-adherence to guideline-recommended cardiovascular medications in adults with PAD. Results will be used to identify evidence-care gaps and inform where interventions may be required to improve clinician prescribing and patient adherence to prescribed medications.

    PROSPERO registration number

    CRD42022362801.

    ❌